KRT18在肺腺癌发展中的作用:综合生物信息学和实验验证
Yongjie Li1,2, Min Zeng3, Yinan Qin4
1School of Pharmacy, Shaoyang University, Shaoyang, 422000, Hunan, China.
Discover oncology
|December 27, 2024
概括
蛋白18 (KRT18) 在肺腺癌 (LUAD) 中升高,与预后不佳和免疫逃避相关. 这项研究强调了KRT18作为LUAD潜在的生物标志物和治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物信息学是一种生物信息学.
背景情况:
- 肺腺癌 (LUAD) 由于发病率和死亡率高,对全球健康构成重大挑战.
- 目前用于高级LUAD的治疗方法通常具有低于最佳的疗效,需要新的生物标志物和治疗点.
研究的目的:
- 研究质素18 (KRT18) 作为预后生物标志物和高级LUAD治疗标的潜力.
- 探索KRT18表达与临床病理特征,免疫透和患者生存的关联.
主要方法:
- 使用TCGA,GEO,HPA和CPTAC数据集进行全面的生物信息学分析.
- 进行了免疫透分析,功能丰富分析和单细胞分析.
- 为了评估预后价值,进行了生存分析 (OS,DSS,PFI).
主要成果:
- 与正常组织相比,KRT18表达在LUAD组织中显著增加,与不良的临床病理特征相关.
- 升高的KRT18与免疫细胞群和与免疫逃避相关的途径有关.
- 高KRT18表达预测了较差的整体存活率,疾病特异性存活率和无进展间隔 (AUC=0.846).
结论:
- KRT18在LUAD中显示出作为预后生物标志物的实用性,表明患者的治疗结果不佳.
- KRT18也可能作为潜在的治疗点,初步证据表明NU.1025可以逆转KRT18调制的瘤特征.
- 需要进一步研究KRT18的机械功能和在LUAD中的临床治疗潜力.
更多相关视频
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10.1K
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
16.6K
相关概念视频
01:20The Retinoblastoma Gene
4.0K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.0K
02:39lncRNA - Long Non-coding RNAs
8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K
02:07Tumor Progression
6.0K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.0K